A Phase 1/2 interventional study of TORL-1-23 and paclitaxel and TORL-1-23 and carboplatin in FIGO Stage III and IV Ovarian Cancer, Fallopian Tube Cancers and Primary Peritoneal Cancer, sponsored by TORL Biotherapeutics, LLC. Recruiting at 7 sites in United States. Open to female participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-07-13.
Sponsored by TORL Biotherapeutics, LLC · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 73 studies testing paclitaxel in Fallopian Tube Neoplasms — 7 open to participants now, 13 under way, 4 of them phase 3. Paclitaxel · Fallopian Tube Neoplasms.
Among the 73 studies testing paclitaxel in Fallopian Tube Neoplasms, this one is the 31st largest by planned enrollment of the 69 interventional ones that give a count, is the only one that started in 2025, is the only one in phase 1/2, reaches primary completion later than 11 of the 12 other live ones, and was the 74th registered.
835 studies on the registry are indexed under Fallopian Tube Neoplasms; 131 are open to participants now.
Browse Fallopian Tube Neoplasms studies →7 of the 73 studies testing paclitaxel in Fallopian Tube Neoplasms are open now, in 5 countries. Recruiting first, the newest first:
Emory University · Sites in United States
Ages 18+ · Women only
The University of Hong Kong · Sites in Hong Kong
Ages 18+ · Women only
Women's Hospital School Of Medicine Zhejiang University · Sites in China
Ages 18–75 · Women only
National Cancer Institute (NCI) · Sites in United States, Puerto Rico
University Health Network, Toronto · Sites in Canada
Ages 18+ · Women only
By country, each count listing its studies:
Paclitaxel: first FDA approval 1992 (TAXOL), first EMA approval 1999. What it is approved for, and how studies give it, is on its page →
Of the 106 Fallopian Tube Neoplasms studies recruiting now, 88 (83%) set no upper age limit and 10 (9%) stop at 75 or younger; 6 take children under 18; 1 takes healthy volunteers.
This study: 18 Years to 75 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
73 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 19 · Phase 2 40 · Phase 3 15
First in 1997; this study’s year is marked.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is above the median of 50 across 684 interventional studies indexed under Fallopian Tube Neoplasms.
Median enrollment 46 across the 69 interventional studies. Of the 50 that completed or were terminated, 23 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 73 have an industry lead sponsor. The 10 most frequent:
TORL Biotherapeutics, LLC is the lead sponsor of 8 studies on the registry; 4 are open to participants now.
TORL Biotherapeutics, LLC has 2 studies filed under Fallopian Tube Neoplasms — fewer than ten, so there is no comparison to draw.
2 of the studies testing paclitaxel in Fallopian Tube Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06492070Emory UniversityCryocompression With or Without Cilostazol for the Prevention of Paclitaxel-induced Neuropathy in Patients With Gynecological Cancers | 2026-12-31 |
| NCT01970722City of Hope Medical CenterSurgery and Chemotherapy With or Without Chemotherapy After Surgery in Treating Patients With Ovarian, Fallopian Tube, Uterine, or Peritoneal Cancer | 2027-01-05 |
Add all 2 to your calendar (.ics) → With an account.
Among the 73 studies testing paclitaxel in Fallopian Tube Neoplasms, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A Phase 1B/2 Study to Investigate the Safety and Efficacy of TORL-1-23 with Chemotherapy Given Before Initial Surgery in Women with Advanced Stage Ovarian Cancer
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Administered once every three weeks
Combination Product: TORL-1-23 and paclitaxel
Administered once every three weeks
Combination Product: TORL-1-23 and carboplatin
Administered once every three weeks
Combination Product: TORL-1-23, paclitaxel, and carboplatin
Drug pages: Ixotatug vedotin · Paclitaxel
TORL-1-23 and paclitaxel
Drug pages: Ixotatug vedotin · Carboplatin
TORL-1-23 and carboplatin
TORL-1-23, paclitaxel, and carboplatin
Characterize the safety and feasibility of TORL-1-23 in combination with chemotherapy by analyzing the incidence of treatment emergent adverse events and serious adverse events.
Incidence of Grade greater than or equal to 3 (using CTCAE V5.0) treatment-emergent adverse event (TEAE) and related serious adverse event (SAE)
Time frame: Treatment during Cycle 1 to Cycle 4 (Each cycle is 21 days)
To assess the efficacy of neoadjuvant TORL-1-23 in combination with chemotherapy
Determination of percentage CRS3 score for each treatment arm
Time frame: postoperative after Cycle 4 (Each cycle is 21 days)
To assess the tolerability of TORL-1-23 in combination with chemotherapy
Safety assessed by incidence of intolerable Grade 2 and Grade greater than or equal to 3 TEAE and related SAE.
Time frame: Treatment up to Cycle 8 (each cycle is 21 days)
To characterize duration of benefit for TORL-1-23 plus chemotherapy
Relapse free survival for participants
Time frame: Measured up to 15 months after surgery
Plan to share: No
No publications or documents are linked to this record.
Started Dec 2025 (actual). Primary completion is estimated for Dec 2027, 24 months after the start.
Of 37 phase 1/2 interventional studies under Fallopian Tube Neoplasms, half reached primary completion within 70 months of starting (the median), counting those still running; a quarter within 56 and three quarters within 110. This study's planned 24 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Ixotatug vedotin · Paclitaxel · Carboplatin
TORL Biotherapeutics, LLC